Programme

The provisional programme for Dalton Discussion 10: Metals in Medicine follows:

Session 1: Metallo-pharmaceuticals

KEYNOTE
The use of transition metal complexes as anti-cancer and anti-HIV agents
Raymond Wai-Yin Sun, Dik-Lung Ma, Ella Lai-Ming Wong and Chi-Ming Che*
University of Hong Kong, Hong Kong 

Effect of charge and pro-drug status on platinum drug-biomolecule interactions
Nicholas P Farrell*
Virginia Commonwealth University, USA 

Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity
Anthony S Humphreys, Aleksandra Filipovska, Susan J Berners-Price*, George A Koutantonis, Brian W Skelton and Allan H White
University of Western Australia, Australia 

Iron-binding properties of plant phenolics and cranberry's bio-effects
Maolin Guo*, Carlos Perez, Elise Rapoza, Yibin Wei and Gregory Su
University of Massachusetts, USA 

New CO-releasing molecules based on cyclopentadienyliron carbonyls
David Scapens, Harry Adams, Tony R Johnson, Brian E Mann*, Philip Sawle, Rehan Aqil, Trevor Perrior and Roberto Motterlini 
University of Sheffield, UK

Session 2: Imaging, diagnosis and labelling

KEYNOTE
Radiometallodrugs in diagnosis and targeted therapy
Helmut Mäcke*
University Hospital Basel, Switzerland 

Copper radiopharmaceuticals for imaging hypoxia
Jason Lewis*
Washington University in St. Louis, USA 

Ru-106 radiolabelling of the antitumor complex, [(Eta6-fluorene)Ru(en)Cl]PF6
James D Hoeschele*, Abraha Habtemariam, Fuyi Wang and Peter J Sadler
Michigan State University, USA 

Synthesis and characterization of a Gd(III) based contrast agent responsive to thiol containing compounds
Carla Carrera, Giuseppe Digilio, Simona Baroni, Daniela Burgio, Simona Consol, Franco Fedeli, Dario Longo, Armando Mortillaro and Silvio Aime*
Universita di Torino, Italy 

Designing Zn(II) and Cu(II) derivatives as probes for in vitro fluorescence imaging
Sofia I Pascu*, Philip A Waghorn, Timothy D Conry, Helen M Betts, Jonathan R Dilworth, Grant C Churchill, Tzveta Pokrovska, Martin Christlieb, Franklin I Aigbirhio and John E Warren
The University of Oxford, UK 

How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies 
Robert C King, M Bashir-Uddin Surfraz, Stefano C G Biagini, Philip J Blower* and Stephen J Mather
King's College London, UK 

Session 3: Design of new drugs and diagnostic agents

KEYNOTE
Metal based drugs: from serendipity to design 
Simon P Fricker*
Canada 

Probing key coordination interactions of novel configurationally restricted metal activated chemokine receptor antagonists
G McRobbie, A Khan, G C Valks, S G Fiddy, L Madden, J Greenman, N A Young and S J Archibald*
University of Hull, UK 

Lanthanide containing compounds for therapeutic care in bone resorption disorders
Cheri A Barta, Kristina Sachs-Barrable, Jessica Jia, Katherine H Thompson, Kishor M Wasan and Chris Orvig*
University of British Columbia, Canada 

Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress
Louise K Charkoudian, David M Pham, Ashley M Kwon, Abbey D Vangeloff and Katherine J Franz*
Duke University, USA 

KEYNOTE
Targeted alpha-therapy: past, present, future?
Martin W Brechbiel*
National Institutes of Health, USA 

The exocyclic functionalisation of bis(thiosemicarbazonate) complexes of zinc and copper: the synthesis of monomeric and dimeric species
Martin Christlieb, Harriet S R Struthers, Paul D Bonnitcha, Andrew R Cowley and Jonathan R Dilworth*
University of Oxford, UK 

Session 4: Metallotherapeutics : novel mechanisms of action

KEYNOTE
Developing new metal based therapeutics: challenges and opportunities
Trevor Hambley*
University of Sydney, Australia 

Novel platinum(II)-based anticancer complexes and molecular hosts as their drug delivery vehicles
Nial J Wheate, Robin I Taleb, Anwen M Krause-Heuer, Rebekah L Cook, Shaoyu Wang, Vincent J Higgins and Janice R Aldrich-Wright*
University of Western Sydney, Australia 

Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy
Paul Dyson*
École Polytechnique Fédérale de Lausanne, Switzerland 

The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif
Elizabeth Hillard, Pascal Pigeon, Anne Vessières, Christian Amatore, and Gérard Jaouen*
Ecole Nationale Supérieure de Chimie de Paris, France 

New group IV complexes as potential anti-tumour drugs
Patrick C McGowan*, Olivia R Allen, Andrew L Gott, Stacey M Lord and J  J Mannion
University of Leeds, UK 

 

* denotes presenter to whom affiliation applies